Myriad Genetics, Inc. (MYGN)

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$5.82+1.04%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Myriad Genetics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	196.11M
EPS	—	-0.181
FY 2026 · Annual
Revenue	$770M–$790M	777.92M
EPS	—	-0.72
FY 2027 · Annual
Revenue	—	820.46M
EPS	—	-0.589

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve adjusted EBITDA of $37M-$49M in 2026	Adjusted EBITDA is targeted between $37M and $49M.	Broken	Adjusted EBITDA falls below $37M in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain adjusted gross margin of 68%-69% in 2026	Gross margin should stay near 68%-69%.	Broken	Gross margin falls below 68% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize management team after recent departures	A supporting condition in Myriad Genetics, Inc.'s published investment case. The stated target is No further key executive departures in next 4 quarters.	Under Pressure	Additional key executive departures occur	2 key executive departures vs 0 target Formal separation of CCO Brian Donnelly and resignation of Director Dr. Skovronsky confirm further management instability. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue of $860M-$880M in 2026	A primary condition in Myriad Genetics, Inc.'s published investment case. The stated target is $860M-$880M total revenue.	Broken	Revenue falls below $818M in FY26	Revenue: $190.7M FY2026-Q4; GAAP. Published target: $860M-$880M total revenue. Target period is not explicitly aligned with this observation. Source published Jul 31, 2026190,700,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 43f99c45-5478-4561-8f1e-175671c7aeb8. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.59

$0.15 → $-0.59 · observed estimates

FY2027 revenue$0.82B

$0.92B → $0.82B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.15	$915,824,890	9 / 9
2026-07-25	$0.15	$915,773,778	5 / 6
2026-07-26	$0.15	$915,824,890	9 / 9
2026-07-27	$0.15	$915,773,778	5 / 6
2026-07-28	$0.15	$915,824,890	9 / 9
2026-07-29	$0.15	$915,824,890	9 / 9
2026-07-30	$0.15	$915,824,890	9 / 9
2026-07-31	$0.15	$915,824,890	9 / 9
2026-08-01	$0.04	$901,645,878	5 / 6
2026-08-02	$-0.07	$881,306,560	9 / 9
2026-08-03	$-0.07	$881,306,560	9 / 9
2026-08-04	$-0.07	$881,306,560	9 / 9
2026-08-05	$-0.07	$881,252,544	5 / 6
2026-08-06	$-0.07	$881,252,544	5 / 6
2026-08-07	$-0.07	$881,252,544	5 / 6
2026-08-08	$-0.34	$845,089,860	8 / 8
2026-08-09	$-0.07	$881,252,544	5 / 6
2026-08-10	$-0.07	$881,252,544	5 / 6
2026-08-12	$-0.41	$834,572,110	8 / 8
2026-08-13	$-0.07	$881,252,544	5 / 6
2026-08-14	$-0.07	$881,252,544	5 / 6
2026-08-15	Unavailable	$881,252,544	4 / 6
2026-08-16	Unavailable	$881,252,544	4 / 6
2026-08-17	Unavailable	$881,252,544	4 / 6
2026-08-18	Unavailable	$881,252,544	4 / 6
2026-08-19	$-0.07	$881,252,544	5 / 6
2026-08-20	$-0.53	$821,558,590	5 / 6
2026-08-21	$-0.53	$821,558,590	5 / 6
2026-08-22	$-0.57	$821,780,812	5 / 6
2026-08-23	$-0.57	$821,780,812	5 / 6
2026-08-24	$-0.57	$821,780,812	5 / 6
2026-08-25	$-0.57	$821,780,812	5 / 6
2026-08-26	$-0.57	$821,780,812	5 / 6
2026-08-27	$-0.57	$821,780,812	5 / 6
2026-08-28	$-0.57	$821,780,812	5 / 6
2026-08-29	$-0.57	$821,780,812	5 / 6
2026-08-30	$-0.57	$821,780,812	5 / 6
2026-08-31	$-0.57	$821,780,812	5 / 6
2026-09-01	$-0.57	$821,780,812	5 / 6
2026-09-02	$-0.58	$820,673,034	5 / 6
2026-09-03	$-0.58	$820,673,034	5 / 6
2026-09-04	$-0.58	$820,673,034	5 / 6
2026-09-05	$-0.58	$820,673,034	5 / 6
2026-09-06	$-0.58	$820,673,034	5 / 6
2026-09-07	$-0.58	$820,673,034	5 / 6
2026-09-08	$-0.58	$820,673,034	5 / 6
2026-09-09	$-0.58	$820,673,034	5 / 6
2026-09-10	$-0.57	$821,155,448	5 / 6
2026-09-11	$-0.57	$821,155,448	5 / 6
2026-09-12	$-0.57	$821,155,448	5 / 7
2026-09-13	$-0.57	$821,155,448	5 / 7
2026-09-14	$-0.57	$821,155,448	5 / 7
2026-09-15	$-0.57	$821,155,448	5 / 7
2026-09-16	$-0.57	$821,155,448	5 / 7
2026-09-17	$-0.57	$821,155,448	5 / 7
2026-09-18	$-0.57	$821,155,448	5 / 7
2026-09-19	$-0.57	$821,155,448	5 / 7
2026-09-20	$-0.57	$821,155,448	5 / 7
2026-09-21	$-0.57	$821,155,448	5 / 7
2026-09-22	$-0.57	$821,155,448	5 / 7
2026-09-23	$-0.57	$821,176,908	5 / 7
2026-09-24	$-0.57	$821,176,908	5 / 7
2026-09-25	$-0.57	$821,176,908	5 / 7
2026-09-26	$-0.57	$821,176,908	5 / 7
2026-09-27	$-0.57	$821,176,908	5 / 7
2026-09-28	$-0.57	$821,176,908	5 / 7
2026-09-29	$-0.57	$821,176,908	5 / 7
2026-09-30	$-0.57	$821,176,908	5 / 7
2026-10-01	$-0.58	$820,963,231	5 / 6
2026-10-02	$-0.58	$820,963,231	5 / 6
2026-10-03	$-0.58	$820,941,009	5 / 6
2026-10-04	$-0.58	$820,941,009	5 / 6
2026-10-05	$-0.58	$820,941,009	5 / 6
2026-10-06	$-0.58	$820,941,009	5 / 6
2026-10-07	$-0.58	$820,941,009	5 / 6
2026-10-08	$-0.59	$820,356,214	5 / 6
2026-10-09	$-0.59	$820,356,214	5 / 6
2026-10-10	$-0.59	$820,356,214	5 / 6
2026-10-11	$-0.59	$820,356,214	5 / 6
2026-10-12	$-0.59	$820,356,214	5 / 6
2026-10-13	$-0.59	$820,378,436	5 / 6
2026-10-14	$-0.59	$820,481,481	5 / 6
2026-10-15	$-0.59	$820,481,481	5 / 6
2026-10-16	$-0.59	$820,481,481	5 / 6
2026-10-17	$-0.59	$820,481,481	5 / 6
2026-10-18	$-0.59	$820,481,481	5 / 6
2026-10-19	$-0.59	$820,481,481	5 / 6
2026-10-20	$-0.59	$820,481,481	5 / 6
2026-10-21	$-0.59	$820,481,481	5 / 6
2026-10-22	$-0.59	$820,478,847	5 / 6
2026-10-23	$-0.59	$820,456,625	5 / 6
2026-10-24	$-0.59	$820,456,625	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	7	2
2026-06-01	2	6	2
2026-07-01	2	5	2
2026-08-01	2	5	2
2026-09-01	2	6	3
2026-10-01	1	6	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 1 Buy / Strong Buy · 6 Hold · 3 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Wells FargoOct 20 · prior Aug 3

$3.00 → $4.50+50.0%

Piper SandlerOct 20 · prior Sep 1

$2.00 → $5.00+150.0%

Craig-HallumOct 2

$8.00New observation · no comparable prior

$0$4.40$8.80

2 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve adjusted EBITDA of $37M-$49M in 2026Published status: Broken
Maintain adjusted gross margin of 68%-69% in 2026Published status: Broken
Stabilize management team after recent departuresPublished status: Under Pressure
Achieve revenue of $860M-$880M in 2026Published status: Broken

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-65.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Myriad Genetics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth and turnaround case in healthcare diagnostics, not a proven durable compounder, because the company remains loss-making. The long-term thesis is in watch status: cancer-testing volumes are growing, but recent financial performance is weak and earnings execution has been uneven.

What's priced into Myriad Genetics, Inc.

The valuation model signals cheapness versus peers, but its confidence is low, and the expectations gap is 0.29. The evidence does not establish what specific growth or improvement the market already assumes, so the cheapness signal alone offers limited support for the thesis.

What the fundamentals likely do

Near term, earnings risk is elevated after recent misses, with a 55% estimated chance of a next-quarter miss; the evidence flags a guidance cut as a negative trigger. In Q2 2026, cancer-care test volume grew 6% year over year, but revenue per test fell 9%, total revenue was lower than in Q1, and operating expenses rose year over year. The sector backdrop has improved, though litigation was reported on October 20 and management’s efficiency efforts have shown limited delivery so far.

What Myriad Genetics, Inc. hinges on

The multi-year thesis hinges on cancer-care volume growth translating into stronger revenue despite reimbursement pressure, and on efficiency efforts reducing losses. Near-term signals include the next guidance update, employment data that could affect sector sentiment, and whether healthcare bellwethers continue to report strong results.